CHENGDU, China, May 1, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today reported that TPI's operation sustained the recent earthquake and the following aftershocks caused by the Ya'an earthquake in Sichuan province on April 20th, 2013. Manufacturing facilities of TPI at Longquan County and Xinjin County of Chengdu have been operating undisturbed during the earthquake and the aftershocks that followed. Ya'an earthquake The Ya'an earthquake occurred at 8:02AM Beijing Time on April 20, 2013 with the epicenter located in Lushan County, Ya'an City, Sichuan, about 72 miles from the capital of Sichuan province, Chengdu. The magnitude of the earthquake was measured at a range of 6.6 to 7.0 by China Earthquake Data Center with 1,815 aftershocks have been recorded within the first 72 hours. The earthquake has resulted in 196 people dead, 24 missing, and at least 11,826 injured with more than 968 seriously injured ( http://en.wikipedia.org/wiki/2013_Lushan_earthquake). About TPI Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit: www.tianyinpharma.comSafe Harbor Statement The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.